

Sandhya Vasan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5448309/publications.pdf>

Version: 2024-02-01

47
papers

1,285
citations

430874

18
h-index

395702

33
g-index

51
all docs

51
docs citations

51
times ranked

2243
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	9
2	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	3.1	6
3	Neurocognitive impact of Zika virus infection in adult rhesus macaques. <i>Journal of Neuroinflammation</i> , 2022, 19, 40.	7.2	11
4	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	73
5	HIV-1 infections with multiple founders associate with the development of neutralization breadth. <i>PLoS Pathogens</i> , 2022, 18, e1010369.	4.7	5
6	Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand. <i>AIDS Research and Therapy</i> , 2022, 19, .	1.7	2
7	Cognitive trajectories after treatment in acute HIV infection. <i>Aids</i> , 2021, 35, 883-888.	2.2	13
8	Factors influencing estimates of HIV-1 infection timing using BEAST. <i>PLoS Computational Biology</i> , 2021, 17, e1008537.	3.2	4
9	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. <i>PLoS Pathogens</i> , 2021, 17, e1009339.	4.7	32
10	Vaccine development lessons between HIV and COVID-19. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 759-761.	9.1	3
11	Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. <i>Frontiers in Immunology</i> , 2021, 12, 710044.	4.8	18
12	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	4.9	2
13	Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. <i>EclinicalMedicine</i> , 2021, 38, 101033.	7.1	4
14	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. <i>PLoS Pathogens</i> , 2021, 17, e1009785.	4.7	12
15	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. <i>Journal of Virology</i> , 2021, 95, e0079721.	3.4	2
16	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	44
17	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	6.0	47
18	Current approaches to HIV vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25793.	3.0	35

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1010105.	4.7	9
20	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23652-23662.	7.1	193
21	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	4.7	33
22	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	3.4	19
23	HIV vaccine delayed boosting increases Env variable region 2â€™specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	5.0	18
24	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020, 5, .	5.0	12
25	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020, 5, .	5.0	12
26	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , 2020, 130, 3299-3304.	8.2	24
27	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	4.7	13
28	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	4.7	73
29	Impact of analytical treatment interruption on the central nervous system in a simian-HIV model. <i>Aids</i> , 2019, 33, S189-S196.	2.2	6
30	Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	33
31	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. <i>PLoS ONE</i> , 2018, 13, e0196397.	2.5	14
32	HIV Vaccine Efficacy Trials: RV144 and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 3-30.	1.6	6
33	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	4.0	57
34	DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers. <i>Journal of Immunology</i> , 2017, 199, 3437-3452.	0.8	7
35	<sc>CD</sc>+ Cell infiltration into subcutaneous adipose tissue is not indicative of productively infected cells during acute <sc>SHIV</sc> infection. <i>Journal of Medical Primatology</i> , 2017, 46, 154-157.	0.6	22
36	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	4.7	38

#	ARTICLE	IF	CITATIONS
37	Transgender populations and HIV: unique risks, challenges and opportunities. <i>Journal of Virus Eradication</i> , 2016, 2, 87-93.	0.5	29
38	Transgender populations and HIV: unique risks, challenges and opportunities. <i>Journal of Virus Eradication</i> , 2016, 2, 87-93.	0.5	17
39	Vaccine Induced Seroreactivity in RV144 Vaccine Recipients in RV305, a Placebo Controlled Assessment of Late Boosts with ALVAC-HIV and AIDSVAX B/E. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A191-A191.	1.1	0
40	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A33-A33.	1.1	11
41	RV306, an Evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A264-A264.	1.1	4
42	A DNA-Based Candidate HIV Vaccine Delivered via <i>In Vivo</i> Electroporation Induces CD4 Responses toward the ± 4127 -Binding V2 Loop of HIV gp120 in Healthy Volunteers. <i>Vaccine Journal</i> , 2012, 19, 1557-1559.	3.1	36
43	<i>In Vivo</i> Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. <i>PLoS ONE</i> , 2011, 6, e19252.	2.5	160
44	Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8617.	2.5	41
45	Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine. <i>PLoS ONE</i> , 2010, 5, e8816.	2.5	47
46	Unique HIV Risk Factors and Prevention Needs for Transgender Women and Cisgender Men Who Have Sex with Men in Bangkok, Thailand. <i>Transgender Health</i> , 0, , .	2.5	0
47	Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	5